Eli Lilly's tirzepatide leads to 50% more weight loss compared to Novo Nordisk's semaglutide in 72-week study.

Eli Lilly said on Sunday its drug Zepbound was superior to Novo Nordisk's Wegovy across five weight-loss targets such as ...

A study of two blockbuster weight-loss drugs showed that users of Eli Lilly’s Zepbound lost just over 2 inches more off their ...

The first head-to-head trial of Mounjaro and Wegovy, the weight-loss drugs, compared the effectiveness of the two leading ...

People taking Eli Lilly's obesity drug, Zepbound, lost nearly 50 per cent more weight than those using rival Novo Nordisk's Wegovy.

Hims & Hers rebounds with key partnerships and launches, achieving 111% YoY revenue growth. Learn more about HIMS stock here.

One weight loss injection has been branded more effective than another, after scientists carry out the first ever ...

Eli Lilly's Zepbound surpassed Novo Nordisk's Wegovy in reducing waist circumference and overall weight loss in a recent ...

Eli Lilly announced that its obesity drug Zepbound outperformed Novo Nordisks Wegovy in a direct comparison across five key ...